chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received vaccine on 02-Apr-2022, post expiry date of 01-Apr-2022.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received vaccine on 02-Apr-2022, post expiry date of 01-Apr-2022.) in a 54-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In April 2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received vaccine on 02-Apr-2022, post expiry date of 01-Apr-2022.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received vaccine on 02-Apr-2022, post expiry date of 01-Apr-2022.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided by the reporter.  The vial was initially stored in the refrigerator on 04-Apr-2022. The vial did not undergo any temperature excursions. It was reported that pharmacist thought that the vaccine expired in Jun-2022, however it was expired on 01-Apr-2022.  Treatment information was not provided.
received only liquid portion; received only liquid portion; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA592A, expiry date 31st August 2022) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details were reported as follows: The age at vaccination was not reported. The registered nurse reported that a patient between 11 and 17 year old received only liquid portion of Menveo, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. She could not tell the exact age of the patient but the patient might be between 11 and 17 years of age. The nurse provided limited information since information was not available regarding the date of vaccination, demographic details from patient who received liquid portion of menveo.  The consent to follow up granted.
T78.40XA HYPERSENSITIVITY REACTION, INIT 6/16/2021 NEUTROPENIA, UNSPECIFIED
10:50am shot was given, 11am patient started to get cold and having a headache, 11:10am patient started to have hard time breathing and severely cold and BP was rising. 911 was called and patient was transported to hospital where she was admitted.
I had a running nose, sneezing, and coughing. I had body aches, headache and loss of taste and smell. I also had brain fog that still continues today. My symptom lasted for about 5 days for the serve symptoms. I still can not really taste everything. On Oct 17th, I tested positive for Covid-19. I also took a home Covid-19 test, positive results.
Symptoms of Shingles started to developed on March 13. Virtual visit doctor confirmed it is Shingles and prescribed Valacyclovir HCL 1 Gram Tablet to take 1 table 3 times a day for 7 days. As of today, the symptoms are not better yet.
I got the shot and still got the shingles/Suspected vaccination failure; Still got the shingles; painful; Miserable; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, pain and feeling miserable. On an unknown date, the outcome of the vaccination failure, shingles, pain and feeling miserable were unknown.   It was unknown if the reporter considered the vaccination failure, shingles, pain and feeling miserable to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 27-FEB-2023 Reporter's Comment: This case was reported by a patient via interactive digital media. The patient reported that he/she received Shingles vaccine. The patient stated that after received Shingles vaccine still he/she experienced shingles which was miserable and painful. Additional supportive information: This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up would not possible as no contact details were available.
This spontaneous report as received from a licensed practical nurse refers to a female patient of unknown age. On an unknown date the patient was vaccinated with a dose of ZOSTAVAX (dose and lot # not reported) for immunization. The nurse reported her friend received ZOSTAVAX at an unspecified date, and developed a rash all over her body. The patient sought medical attention by office visit and was given no treatment. No lab diagnostics studies were performed. At the time of reporting the patient's outcome was unknown. Additional information is not expected.
Patient describes nerve pain starting in legs and moving through body the following day. She did not seek treatment but stopped by pharmacy to inquire about adverse event. Possible Guillain Barre Syndrome.
This spontaneous report as received from a pharmacy manager via Pfizer pharmacy representative (manufacturer control number 2018405472) refers to a female patient of unknown age. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On an unknown date, the patient was vaccinated with PNEUMOVAX 23 (dose, route of administration, lot# and expiration date were not provided). On an unknown date, the patient experienced injection site pain. The outcome of injection site pain was unknown. The causality assessment was not provided.
some hearing loss in left ear; Ear ringing; This is a spontaneous report from a contactable other health professional (patient). A 39-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration at the age of 39-years-old on 24Feb2021 18:00 (Lot Number: EL8982) as a single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient had no known allergies. The patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on 03Feb2021 6:00 PM (Lot Number: unknown) as a single dose for COVID-19 immunization. The patient experienced some hearing loss in left ear (medically significant) and ear ringing on 03Mar2021 19:00. Unknown if patient received treatment. The outcome of the events was not recovered. The patient was not pregnant. Facility type vaccine was Hospital. No other vaccine in four weeks. No COVID prior vaccination. Not COVID tested post vaccination.; Sender's Comments: Based on chronological connection to the vaccine a causal relationship between reported events and BNT162B2 vaccine cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
She had Pain: Headache or Migraine after the vaccine. Onsite EMS was requested.BP 142/86 HR 86  99% O2 on room air.  They were able to find a specific cause and she refused additional workup
pt states 24 hrs p/vax 16APR93 reported to work & was told eyes & skin were yellow & was sent home; did not see a pvt MD & that on 18APR93 eyes & sking nl;
shoulder is burning/stinging; big oval mark at injection site; little itchy; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE PAIN (shoulder is burning/stinging), VACCINATION SITE RASH (big oval mark at injection site) and VACCINATION SITE PRURITUS (little itchy) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No Medical History information was reported.  Concomitant products included VITAMIN D3 and VALACYCLOVIR [VALACICLOVIR] for an unknown indication.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced VACCINATION SITE PAIN (shoulder is burning/stinging), VACCINATION SITE RASH (big oval mark at injection site) and VACCINATION SITE PRURITUS (little itchy). At the time of the report, VACCINATION SITE PAIN (shoulder is burning/stinging), VACCINATION SITE RASH (big oval mark at injection site) and VACCINATION SITE PRURITUS (little itchy) outcome was unknown.            Concomitant product use include B complex with biotin.  Action taken with mRNA-1273 in response to the event was not applicable.  patient got the second dose after a month of the first dose.   Most recent FOLLOW-UP information incorporated above includes: On 11-May-2021: Patients age was added. Reporters email address added. Second dose information added.
There was also noticeable pain, like a headache behind my left eye; I had double vision when I looked up out of the top half of my eyes; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 50 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 08Oct2021 13:00 (Lot number: FF8839) at the age of 50 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Ankylosing spondylitis" (unspecified if ongoing); "known allergies: Sulfa" (unspecified if ongoing), notes: Sulfa, barley; "known allergies: barley" (unspecified if ongoing), notes: Sulfa, barley. The patient's concomitant medications were not reported. Vaccination history included: Pfizer (Dose Number: 2, Batch/Lot No: EP6955, Location of injection: Arm Left, Vaccine Administration Time: 03:00 PM), administration date: 26Mar2021, when the patient was 50 years old, for Covid-19 Vaccination; Pfizer (Dose Number: 1, Batch/Lot No: EN6199, Location of injection: Arm Left, Vaccine Administration Time: 03:00 PM), administration date: 04Mar2021, when the patient was 50 years old, for Covid-19 Vaccination. The following information was reported: DIPLOPIA (non-serious) with onset 11Oct2021 03:00, outcome "recovered" (2021), described as "I had double vision when I looked up out of the top half of my eyes"; HEADACHE (non-serious) with onset 11Oct2021 13:00, outcome "recovered" (2021), described as "There was also noticeable pain, like a headache behind my left eye". The events "i had double vision when i looked up out of the top half of my eyes" and "there was also noticeable pain, like a headache behind my left eye" were evaluated at the physician office visit. Therapeutic measures were not taken as a result of diplopia, headache.  Additional information: Beginning 2.5 days after the booster shot, she had double vision when she looked up out of the top half of her eyes. The images were one on top of the other. There was also noticeable pain, like a headache behind my left eye. The double vision finally went away after about 4.5 weeks. She had gone in to her eye doctor twice and found no abnormalities to explain her double vision. The patient was not tested positive for covid 19 prior to vaccination and had not been tested post vaccination. Patient did not receive any other vaccines within 4 weeks and received other unspecified medications within 2 weeks to the COVID vaccine.  No follow-up attempts are possible. No further information is expected.
Headache, fever 101, achy all over, sinuses, fatique, right arm swollen red all over, rash under arm, very painful. took Ibuprophen. In bed all day in pain. First dose just sore arm ONLY.   I AM A REDHEAD, Allergic reaction to over 65 Flu shot and 1st dose of Shingles. Do no have information on those. Same reactions as the covid vaccinations.
My asthma cough started on 4/4 in the morning. I cheat was right and I was coughing just like I do when I get sick and my asthma acts up. I used my albuterol inhaler all day and it helped. I had no cough prior to getting the vaccination.
devel fever 102 & chills on 10OCT98 9PM;by 11OCT98 3PM fever gone, hives appeared on opposite arm;
Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. On an unspecified date the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles.  The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. The patient was treated at a health facility for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has  suffered  and will  continue  to  suffer  significant medical expenses, pain and suffering, and other damages. Additional information has been requested.
Patient received MENACTRA after being properly screened by the pharmacist. A minute later the patient was faint and felt nauseous. His BP was 68/44. He retained consciousness and the paramedics were called. He left with the paramedics. They recorded his BP as 100/70.
The vail was initially stored in refrigerator on 08-Mar-2022 and administered on 27-May-2022; administered Moderna COVID-19 vaccine after the 30 day beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered Moderna COVID-19 vaccine after the 30 day beyond use date) and PRODUCT STORAGE ERROR (The vail was initially stored in refrigerator on 08-Mar-2022 and administered on 27-May-2022) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L21A) for COVID-19 prophylaxis.     The patient had no known allergies. The patient was not diagnosed with / tested positive for COVID-19.     On 27-May-2022 at 2:00 PM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 27-May-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered Moderna COVID-19 vaccine after the 30 day beyond use date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vail was initially stored in refrigerator on 08-Mar-2022 and administered on 27-May-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered Moderna COVID-19 vaccine after the 30 day beyond use date) and PRODUCT STORAGE ERROR (The vail was initially stored in refrigerator on 08-Mar-2022 and administered on 27-May-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that, the patient was administered Moderna COVID-19 vaccine after the 30 days beyond use date. The patient had not reported any symptoms. The vial was initially stored in refrigerator on 08-Mar-2022 and the vial did not undergo temperature excursion. No additional doses, medications, or treatments were administered.   This case was linked to MOD-2022-583062 (Patient Link).
Knot developed in right leg and patient had "jerky-like" movements for 2 weeks after vaccination.
Red scaling rash at site of vaccine. Increased in size over 3 days and stabilized. Treatment with topical Hydrocortisone and cool compresses.
Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant) in a female patient of an unknown age (gravida 2, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025220A) for COVID-19 vaccination.     The patient's past medical history included Insomnia and Subfertility (female) (Not ovulating so was given IVF.). Concomitant products included TRAZODONE for Insomnia, PROGESTERONE (ENDOMETRIN) and MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 03-Sep-2021. On 04-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant). On 04-Jan-2021, EXPOSURE DURING PREGNANCY (Pregnant) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided by the reporter. Patient had reported previous pregnancy with live birth having no issues Jun-2017.; Reporter's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female with age unknown. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Moderna COVID-19 Vaccine EUA Fatigue and brain fog starting 24 hours after injection; muscle pain and "grating" shoulder in the arm, "Covid Arm". After about  72 hours the physical symptoms were negligible (other than the Covid Arm rash), but I began having serious trouble with my short term memory. I could not remember things I'd been told or done just a few minutes before - or, rather, I knew I did them, but I could not remember specifics like the name of the food I had ordered or what the actual order was. I could not tell a salesperson in what I needed, what it was called specifically. (Thankfully I had a list to give him.)  I planted a flowerbed and then could not remember what I had planted. Five minutes later I knew I had planted a flower bed, but could not remember which of the two beds it was OR what I'd planted. That sort of thing. I am having hell naming things - if it's got a proper name, I'm really struggling to find it. Nouns. I received the second vaccine on Thursday night and this started on Monday, and today is Tuesday (I think) and it's still going on.
Patient reported anaphylactic type symptoms with swelling of her throat, shortness of breath, wheezing within 15-20 minutes after vaccination.  Patient was taken to ER for further evaluation.
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapy were not reported. On 23-APR-2016, the patient was vaccinated with a first dose of ZOSTAVAX (exact dose, route of administration, lot number and expiry date were not reported) for prophylaxis and on 25-AUG-2017, he/she was inadvertently administered a second dose of ZOSTAVAX (exact dose, route of administration, lot number and expiry date were not reported) for prophylaxis. The lot # and expiration date for the sterile diluent used to reconstitute the ZOSTAVAX was not provided. No adverse effects were reported.
Pt describes HA, nausea, vertigo, fatigue (this did not happen with previous 3 vaccines)
I started having nightly headaches exactly 36 hours after the second dose vaccine.  It happened every night for five days followed by every other night until now.; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old, male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955/ER8733) via an unspecified route of administration in the left arm on 26Mar2021 at 10:00 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. No relevant medical history reported. The patient reported of no known allergies to medications, food, or other products. The patient did not receive any concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 05Mar2021 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 21:00, the patient experienced nightly headaches exactly 36 hours after the second dose of the vaccine. The patient reported that it happened every night for five days followed by every other night until now. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the event started having nightly headaches exactly 36 hours after the second dose vaccine was resolving.   No follow-up attempts are possible. No further information is expected.
24 hours after second dose of Moderna vaccine, patient came down with a fever, aches and pains, and chills that lasted approx. 72 hours. After this time, patient reported a swollen red circle about two inches below injection site that went away after 48 hours. One week after second dose, patient is experiencing swollen, itchy eyelids and hives on face and chin.
episodes of shingles; one dose of Shingrix approximately in March 2019; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 93-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (had multiple episodes of shingles (prior to Shingrix)) and chemotherapy.   In March 2019, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles and incomplete course of vaccination. On an unknown date, the outcome of the shingles and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not applicable for 2nd dose of vaccine. The patient had chemotherapy and multiple episodes of shingles prior to Shingrix vaccination.  This patient received one dose of Shingrix approximately in March 2019 and told that he was not informed he needed a second dose. Also, patient continued having episodes of shingles after 1st dose. Till the time of reporting patient did not receive 2nd dose of Shingrix which led to incomplete course of vaccination.